Background The microencapsulation is an ideal solution to overcome immune rejection without immunosuppressive treatment. Poor biocompatibility and small molecular antigens secreted from encapsulated islets induce fibrosis infiltration. Therefore, the aims of this study were to improve the biocompatibility of microcapsules by dexamethasone coating and to verify its effect after xenogeneic transplantation in a streptozotocin-induced diabetes mice.
Methods Dexamethasone 21-phosphate (Dexa) was dissolved in 1% chitosan and was cross-linked with the alginate microcapsule surface. Insulin secretion and viability assays were performed 14 days after microencapsulation. Dexa-containing chitosan-coated alginate (Dexa-chitosan) or alginate microencapsulated porcine islets were transplanted into diabetic mice. The fibrosis infiltration score was calculated from the harvested microcapsules. The harvested microcapsules were stained with trichrome and for insulin and macrophages.
Results No significant differences in glucose-stimulated insulin secretion and islet viability were noted among naked, alginate, and Dexa-chitosan microencapsulated islets. After transplantation of microencapsulated porcine islets, nonfasting blood glucose were normalized in both the Dexa-chitosan and alginate groups until 231 days. The average glucose after transplantation were lower in the Dexa-chitosan group than the alginate group. Pericapsular fibrosis and inflammatory cell infiltration of microcapsules were significantly reduced in Dexa-chitosan compared with alginate microcapsules. Dithizone and insulin were positive in Dexa-chitosan capsules. Although fibrosis and macrophage infiltration was noted on the surface, some alginate microcapsules were stained with insulin.
Conclusion Dexa coating on microcapsules significantly suppressed the fibrotic reaction on the capsule surface after transplantation of xenogenic islets containing microcapsules without any harmful effects on the function and survival of the islets.
Citations
Citations to this article as recorded by
Engineering superstable islets-laden chitosan microgels with carboxymethyl cellulose coating for long-term blood glucose regulation in vivo Haofei Li, Weijun He, Qi Feng, Junlin Chen, Xinbin Xu, Chuhan Lv, Changchun Zhu, Hua Dong Carbohydrate Polymers.2024; 323: 121425. CrossRef
Investigation of encapsulation of pancreatic beta cells and curcumin within alginate microcapsules Zahra Hosseinzadeh, Iran Alemzadeh, Manouchehr Vossoughi The Canadian Journal of Chemical Engineering.2024; 102(2): 561. CrossRef
A Case for Material Stiffness as a Design Parameter in Encapsulated Islet Transplantation Courtney D. Johnson, Helim Aranda-Espinoza, John P. Fisher Tissue Engineering Part B: Reviews.2023; 29(4): 334. CrossRef
Improved membrane stability of alginate-chitosan microcapsules by crosslinking with tannic acid Li Chen, Fang Jiang, Haidan Xu, Yaoyao Fan, Cunbin Du Biotechnology Letters.2023; 45(8): 1039. CrossRef
Advances in alginate encapsulation of pancreatic islets for immunoprotection in type 1 diabetes Dinesh Chaudhary, Tiep Tien Nguyen, Simmyung Yook, Jee-Heon Jeong Journal of Pharmaceutical Investigation.2023; 53(5): 601. CrossRef
Emerging strategies for beta cell transplantation to treat diabetes Jesus Paez-Mayorga, Izeia Lukin, Dwaine Emerich, Paul de Vos, Gorka Orive, Alessandro Grattoni Trends in Pharmacological Sciences.2022; 43(3): 221. CrossRef
Layer-by-Layer Cell Encapsulation for Drug Delivery: The History, Technique Basis, and Applications Wenyan Li, Xuejiao Lei, Hua Feng, Bingyun Li, Jiming Kong, Malcolm Xing Pharmaceutics.2022; 14(2): 297. CrossRef
β cell replacement therapy for the cure of diabetes Joonyub Lee, Kun‐Ho Yoon Journal of Diabetes Investigation.2022; 13(11): 1798. CrossRef
Modern pancreatic islet encapsulation technologies for the treatment of type 1 diabetes P. S. Ermakova, E. I. Cherkasova, N. A. Lenshina, A. N. Konev, M. A. Batenkin, S. A. Chesnokov, D. M. Kuchin, E. V. Zagainova, V. E. Zagainov, A. V. Kashina Russian Journal of Transplantology and Artificial Organs.2021; 23(4): 95. CrossRef
Min Jung Kim, Eun Hee Kim, Mi Seon Shin, Joo Hui Kim, Hee Kyung Na, Seong Joon Park, Sang Ah Lee, Eun Hee Koh, Woo Je Lee, Ki Ho Song, Joong Yeol Park, Ki Up Lee, Gu Hwan Kim, Han Wook Yoo, Min Seon Kim
Endocrinol Metab. 2011;26(2):171-176. Published online June 1, 2011
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the occurrence of multiple tumors in the parathyroid gland, pancreatic islet, and pituitary gland. This condition is caused by mutations of MEN1, a tumor suppressor gene. Thus far, 565 different germline and somatic mutations of the MEN1 gene have been reported. Herein, we describe the case of a 23-year-old woman who suffered from a repetitive loss of consciousness. After workup, the patient was diagnosed with MEN1 with insulinoma, hyperparathyrodism due to parathyroid adenoma, and non-functioning pituitary microadenoma. She underwent a partial parathyroidectomy and distal pancreatectomy. Familial screening of MEN1 revealed that her brother had prolactinoma, hyperparathyroidism, pancreatic gastrinoma and non-functioning adrenal adenoma. Her father had hyperparathyroidism, pancreatic tumor, and adrenal adenoma. Upon genetic analysis of the MEN1 gene, a novel mutation in the MEN1 gene (exon 1, c.251del; p.Ser84LuefsX35) was detected in the patient, as well as her father and brother.
Citations
Citations to this article as recorded by
Parathyroid disorder and concomitant thyroid cancer in patients with multiple endocrine neoplasia type 1 Ying Wang, Sheng Cai, He Liu, Rui-Na Zhao, Xing-Jian Lai, Ke Lv, Yu-Xin Jiang, Jian-Chu Li Medicine.2021; 100(36): e27098. CrossRef
Genetic and Epigenetic Analysis in Korean Patients with Multiple Endocrine Neoplasia Type 1 Yoon Jung Chung, Sena Hwang, Jong Ju Jeong, Sun Yong Song, Se Hoon Kim, Yumie Rhee Endocrinology and Metabolism.2014; 29(3): 270. CrossRef